Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05742867 · ClinicalTrials.gov registry record
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 115
- Enrollment target
NCT05742867 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 115 participants.
The verdict
NCT05742867 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
Study Summary
The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment attributes for post-RC treatment in Japan.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2024-07-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05742867
The ClinicalTrials.gov registry entry for NCT05742867 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05742867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05742867 about?
NCT05742867 is a clinical study titled "A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder". The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment attributes for post-RC treatment in Japan.
What is the current status of trial NCT05742867?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2023-05-31. Estimated completion is 2024-07-10.
Who is sponsoring clinical trial NCT05742867?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.